https://www.selleckchem.com/products/apx2009.html Current assays based on the 0-hour/1-hour (0-/1-h) algorithm using high-sensitivity cardiac troponin (hs-cTn) are limited to only Abbott Architect hs-cTnI, Siemens Vista hs-cTnI, and Roche Elecsys hs-cTnT. This study aimed to evaluate this new hs-cTnI assay, LumipulsePresto hs Troponin I, for diagnosis of acute myocardial infarction (AMI) on admission and on 0-/1-h algorithm to stratify AMI patients precisely. This prospective cohort study included 442 patients with suspected non-ST-elevation myocardial infarction in three hospitals in Japan and Taiwan from June 2016 to January 2019. We enrolled patients presenting to the emergency department with symptoms suggestive of AMI and collected blood samples on admission and 1 hour later. Two independent cardiologists centrally adjudicated final diagnoses; all clinical information was reviewed twice first, using serial hs-cTnT (Roche-Elecsys, primary analysis) and Lumipulse Presto Lumipulse Presto, second, using the Lumipulse Presto hs-cTnI measurements. At fi clinical utility of the novel LumipulsePresto hs-cTnI assay are high and comparable with the established hs-cTn assays. Diagnostic accuracy and clinical utility of the novel LumipulsePresto hs-cTnI assay are high and comparable with the established hs-cTn assays. Cochlear implant (CI) sound-processing strategies are important to the overall success of a CI recipient. This study aimed to determine the effects of 2 Advanced Bionics (AB) CI-processing strategies, Optima-S and Optima-P, on speech recognition outcomes in adult CI users. A retrospective chart review was completed at a tertiary academic medical center. Seventeen post-lingually deafened adult CI users (median age = 58.6 years; age range 23.5-78.9 years) with long-term use of a paired sound-processing strategy (Optima-P) were reprogrammed with a sequential strategy (Optima-S). Demographic data and speech recognition scores with pre- and post-intervention analy